MannKind stock slumps despite cashing in on United deal

You are here: Home > Biotech > Current Article

MannKind stock slumps despite cashing in on United deal

By Staff Report / Monday, April 1st, 2019 / Comments Off on MannKind stock slumps despite cashing in on United deal

MannKind shares tumbled more than 8 percent in midday trading April 1, despite an announcement that the company had received the first milestone payment in its deal with United Therapeutics. United paid $12.5 million to Westlake Village-based MannKind for its inhalable dry powder version of United’s high blood pressure therapy treprostinil. The new delivery mechanism…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.